Research programme: skin disorder therapeutics - Dermira
Alternative Names: QLT-450; VAL-003Latest Information Update: 28 Nov 2021
Price :
$50 *
At a glance
- Originator QLT
- Developer Dermira
- Class Small molecules
- Mechanism of Action Enzyme inhibitors; Immunomodulators; Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acne; Atopic dermatitis; Vitiligo
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in Acne in USA (Topical)
- 28 Nov 2021 No recent reports of development identified for preclinical development in Atopic-dermatitis in USA (Topical)
- 28 Nov 2021 No recent reports of development identified for preclinical development in Vitiligo in USA (Topical)